Contineum Therapeutics, Inc. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Contineum disclosed a corporate presentation (dated July 2026) detailing its clinical pipeline. PIPE-791, an LPAR1 antagonist, has a Phase 2 IPF trial underway with ~324 subjects (1:1:1 placebo/Dose A/Dose B randomization), estimated completion June 2028. A Phase 1B chronic pain trial (43 subjects: 23 osteoarthritis, 20 lower back pain) showed favorable safety and exploratory efficacy trends. PIPE-307 (JNJ-5120), an M1R antagonist for MDD, is partnered with Janssen under a $1B milestone agreement ($50M upfront, $25M equity investment, low-double-digit to high-teens royalties). IP protection extends through 2042 for PIPE-791. The company projects cash runway through mid-2029.
Why this rating
Presentation is routine disclosure of known development stage and partnership. No material new financial, regulatory, or clinical outcomes reported; milestone/royalty terms previously announced. Small company executing plan on expected timeline.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.